Tigecycline

Kathryn Dzintars, Pharm.D., BCPS
Tigecycline is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Complicated skin and skin structure infections (including those caused by MRSA and vancomycin-susceptible E. faecalis).
    • Author’s comment: avoid in severe infections +/- bacteremia.
  • Complicated intra-abdominal infections (as a single agent).
    • Author’s comment: avoid in severe infections +/- bacteremia.
  • Community-acquired bacterial pneumonia caused by S. pneumoniae (PCN-susceptible isolates), H. influenzae (beta-lactamase negative isolates), and Legionella pneumophila.
    • Author’s comment: not a first-line agent and generally not used for CAP.

NON-FDA APPROVED USES

  • HAP/VAP due to MDR GNR, but high rates of clinical failure reported[5].
    • In critically ill patients, consider using tigecycline in combination with carbapenem or colistin.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: December 4, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Tigecycline ID - 540549 A1 - Dzintars,Kathryn,Pharm.D., BCPS Y1 - 2018/12/04/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540549/all/Tigecycline PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -